A new probiotic bacteria called Bacillus paramycoides strain SCS_MS2 successfully killed four types of harmful bacteria in laboratory tests and survived stomach acid with a 77% survival rate, according to research published in 2026. Gram Research analysis shows this discovery from cheese whey could eventually offer an alternative to antibiotics for fighting resistant infections, though human testing is still needed before any treatments become available.
Scientists discovered a new type of beneficial bacteria called Bacillus paramycoides strain SCS_MS2 that could help fight dangerous infections resistant to antibiotics. The bacteria was found in an unexpected place: cheese whey processed through a special microbial fuel cell. In lab tests, this new probiotic showed strong ability to kill harmful bacteria like E. coli and Staph aureus, survive stomach acid, and tolerate salty conditions. Researchers believe this discovery could lead to new probiotic treatments for humans and animals, offering a promising alternative as antibiotic resistance becomes a growing global health threat.
Key Statistics
A 2026 research article published in Anais da Academia Brasileira de Ciencias identified Bacillus paramycoides strain SCS_MS2, a new probiotic bacteria that demonstrated inhibitory activity against four harmful bacteria species including E. coli and Staphylococcus aureus.
The newly discovered Bacillus paramycoides strain SCS_MS2 maintained a 77% survival rate when exposed to pH 2 conditions (stomach acid), exceeding the survival requirements for many existing commercial probiotics.
Laboratory testing showed Bacillus paramycoides strain SCS_MS2 tolerated salt concentrations up to 6.5% NaCl and demonstrated notable antioxidant activity with low cytotoxicity to human cells, indicating strong probiotic potential.
The Quick Take
- What they studied: Whether a newly discovered bacteria found in cheese whey could work as a probiotic to fight harmful bacteria and antibiotic-resistant infections
- Who participated: Laboratory testing of a bacterial strain isolated from a cheese whey-microbial fuel cell system; no human or animal subjects were involved in this initial research
- Key finding: The new Bacillus paramycoides strain SCS_MS2 successfully killed four types of harmful bacteria in lab tests and survived harsh stomach conditions (pH 2) with a 77% survival rate
- What it means for you: This discovery could eventually lead to new probiotic supplements or treatments to help fight infections, especially those resistant to antibiotics. However, this is early-stage research and human testing would be needed before any products reach consumers
The Research Details
Researchers isolated bacteria from an unusual source: a microbial fuel cell that processes cheese whey (the liquid left over from cheese making). They identified the bacteria using genetic testing (16S rRNA gene sequencing) and confirmed it was a species called Bacillus paramycoides. They then ran a series of laboratory tests to see how well this bacteria could fight harmful microbes and survive in conditions similar to the human digestive system.
The team tested the new strain against four common disease-causing bacteria: Shigella boydii, Escherichia coli (E. coli), Shigella dysenteriae, and Staphylococcus aureus (Staph). They also tested whether it could survive in very acidic conditions (like stomach acid), tolerate salt, stick to surfaces to form protective biofilms, and produce antioxidants without harming human cells.
This research approach is important because it searches for probiotics in non-traditional sources, which could discover new beneficial bacteria we haven’t found before. The specific testing methods used here—checking for acid resistance, salt tolerance, and biofilm formation—are the standard ways scientists determine if a bacteria has real probiotic potential. By finding bacteria in an industrial waste stream (cheese whey), researchers show that valuable probiotics might be hiding in unexpected places, making them easier and cheaper to produce.
This is laboratory-based research that demonstrates the bacteria’s properties in controlled conditions. The genetic identification using 16S rRNA sequencing is a gold-standard method for identifying bacteria species. However, this is early-stage research—the bacteria has only been tested in test tubes and petri dishes, not in living organisms. Before this could become a real treatment, it would need testing in animals and then humans to prove it’s safe and effective
What the Results Show
The newly discovered Bacillus paramycoides strain SCS_MS2 showed strong ability to kill four types of harmful bacteria commonly associated with food poisoning and infections. In laboratory tests, the bacteria demonstrated what scientists call ‘inhibitory activity,’ meaning it produced substances that stopped these harmful microbes from growing.
The strain proved remarkably resilient in harsh conditions. When exposed to pH 2 (extremely acidic, similar to stomach acid), it maintained a 77% survival rate—meaning most of the bacteria survived the journey through the digestive system. It also tolerated salt concentrations up to 6.5% NaCl, which is important because probiotics need to survive in various body environments.
Additionally, the bacteria showed good ‘cell surface hydrophobicity’ and ‘auto-aggregation capability,’ which are fancy ways of saying it can stick to surfaces and clump together. This ability helps probiotics form biofilms—protective layers that help them colonize the gut and resist being washed away. The strain also produced antioxidants (substances that fight cellular damage) while showing low toxicity to human cells.
The bacteria’s antioxidant activity is particularly noteworthy because oxidative stress contributes to many diseases and aging. The fact that strain SCS_MS2 produced these protective compounds while remaining non-toxic to human cells suggests it could potentially offer additional health benefits beyond simply fighting harmful bacteria. The researchers also noted the bacteria’s ability to grow at pH 2 with high survival rates, which exceeds the requirements for many existing probiotics.
According to Gram Research analysis, the discovery of probiotics from industrial waste streams like cheese whey represents a growing trend in probiotic research. While many commercial probiotics come from traditional fermented foods, finding beneficial bacteria in byproducts could make probiotics more sustainable and affordable to produce. The specific properties of strain SCS_MS2—particularly its acid and salt tolerance combined with antimicrobial activity—place it among the more promising candidates identified in recent years, though direct comparisons to other strains would require additional research.
This research was conducted entirely in laboratory conditions using test tubes and petri dishes. The bacteria has not been tested in living animals or humans, so we don’t know yet if it will actually work as a probiotic in real bodies. The study doesn’t specify the exact sample size or provide detailed statistical analysis of the results. Additionally, while the bacteria showed promise against four specific harmful bacteria, it hasn’t been tested against many other pathogens. Before this could become a commercial product, extensive safety testing and clinical trials in humans would be necessary
The Bottom Line
This research is too early-stage to make specific recommendations for consumers. The findings suggest Bacillus paramycoides strain SCS_MS2 has strong potential as a probiotic, but it requires further testing in animals and humans before any products could be developed. If you’re interested in probiotics now, stick with established commercial strains that have human safety data. This discovery should be viewed as promising early research that may lead to future treatments.
This research is most relevant to scientists, pharmaceutical companies, and healthcare providers interested in developing new antibiotics alternatives. It’s also important for people concerned about antibiotic resistance. However, the general public should not expect this to become available as a treatment in the near future. Farmers and the agricultural industry may eventually benefit if this strain proves safe and effective in animals.
This is basic research, not a clinical product. Typically, it takes 5-10 years or more for a promising laboratory discovery to become an approved treatment for humans. The next steps would be animal testing (1-3 years), followed by human safety trials (2-5 years), and regulatory approval. Don’t expect this specific strain to be available as a consumer product for several years at minimum
Frequently Asked Questions
What is Bacillus paramycoides and why is it important?
Bacillus paramycoides strain SCS_MS2 is a newly discovered beneficial bacteria that killed four types of harmful bacteria in lab tests and survived stomach acid with 77% survival rate. It could potentially become a probiotic treatment alternative to antibiotics, though human testing is still needed.
Can I buy this probiotic strain right now?
No, this is early-stage laboratory research. The bacteria has only been tested in test tubes, not in living organisms. It would require animal testing and human clinical trials before any product could be approved for consumers, likely taking several years.
How does this help fight antibiotic resistance?
Antibiotic-resistant bacteria are becoming a major health threat. Probiotics like this strain could help fight infections by producing natural antimicrobial substances and supporting the immune system, offering an alternative when antibiotics don’t work.
Where did scientists find this bacteria?
Researchers discovered Bacillus paramycoides strain SCS_MS2 in cheese whey processed through a microbial fuel cell—an industrial waste stream. This shows beneficial bacteria can be found in unexpected places, potentially making probiotics cheaper and more sustainable to produce.
Is this bacteria safe for humans?
Laboratory tests showed low toxicity to human cells and good survival in stomach acid conditions, suggesting safety potential. However, comprehensive safety testing in animals and humans is required before any medical use. Current research is too preliminary to confirm human safety.
Want to Apply This Research?
- If users are taking probiotics, they could track digestive symptoms (bloating, regularity, energy levels) on a weekly basis using a simple 1-10 scale to monitor changes over time
- Users interested in probiotics could use the app to set reminders for taking their current probiotic supplement consistently, as regular use is necessary for benefits. They could also log dietary sources of probiotics like yogurt, kefir, or fermented foods
- Create a long-term digestive health dashboard where users track multiple indicators (energy, digestion, immune symptoms) over months to identify patterns and correlations with probiotic use
This research describes early-stage laboratory findings about a newly discovered bacterial strain. The bacteria has not been tested in humans or animals and is not available as a commercial product. Do not attempt to self-treat infections or replace prescribed antibiotics based on this research. Anyone interested in probiotic supplements should consult with a healthcare provider before starting new treatments. This article is for educational purposes only and should not be considered medical advice. Always follow guidance from qualified healthcare professionals regarding infection treatment and probiotic use.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.